Philips Debuts Noninvasive Ventilator With High Flow Therapy to Improve Patient Care

AMSTERDAM, November 19, 2018/PRNewswire-FirstCall/ --

 

- Philips V60 Plus ventilator receives CE Mark, expands on Philips` commitment and leadership in hospital respiratory care

- New comprehensive solution enhances clinician workflow and maximizes equipment efficiency to help drive earlier intervention in respiratory distress

 

Royal Philips [https://www.philips.com ] (NYSE: PHG) (AEX: PHIA), a global leader in health technology, today announced the Philips V60 Plus ventilator has received CE mark approval. This comprehensive solution expands on Philips` noninvasive ventilation (NIV) gold standard platform, integrating both NIV and high flow therapy (HFT) in a single device. Clinicians can rapidly adjust therapies around constantly changing patient conditions without having to switch devices. Designed for early intervention in respiratory failure, the V60 Plus enables clinicians to further enhance patient outcomes with less invasive respiratory care therapies, while improving clinician workflow and maximizing equipment investments.

(Photo: https://mma.prnewswire.com/media/786730/Philips_V60_Plus.jpg )

(Photo: https://mma.prnewswire.com/media/786731/V60_Plus.jpg )

Patients with acute respiratory failure require immediate attention from caregivers. While early implementation with NIV is associated with less endotracheal intubation, as well as the reduction of serious complications and adverse events in the ICU [1], clinicians sometimes face challenges when weaning patients off of this therapy. The V60 Plus now delivers a wide range of non-invasive support for these patients, which supports clinicians to begin the weaning process sooner. By having the different, but complementary modes in one device, the V60 Plus can simplify both workflow and device availability.